FDA Clears Roche and Eli Lilly Alzheimer Blood Test
The FDA has cleared Roche and Eli Lilly to market a new blood test designed to help detect signs of Alzheimer disease in older adults experiencing cognitive decline. The biomarker test offers a less invasive alternative to traditional PET scans and spinal fluid tests.
Xurve View
Insights:
Xurve View
ROCHE HOLDING AG-BR and partner ELI LILLY & CO secured United States regulatory clearance for an Alzheimer's blood test. The Elecsys pTau217 biomarker test targets patients aged 55 and older with cognitive decline.
